Hematopoiesis News Volume 3.19 | May 15 2012

LABORATORY RESEARCH

Targeting Anti-Apoptotic A1/Bfl-1 by In Vivo RNA Interference Reveals Multiple Roles in Leukocyte Development in Mice
Scientists highlight the critical role of A1 in leukocyte development and homeostasis, constituting valuable tools for investigating presumed roles of this Bcl-2 family member in immunity, tumorigenesis and drug-resistance. [Blood] Abstract

The Recombinant Human Complement Receptor 2/Factor H Fusion Protein TT30 Protects Paroxysmal Nocturnal Hemoglobinuria Erythrocytes from Both Complement Mediated Hemolysis and C3 Fragment Opsonization
Researchers investigated, in an in vitro model, the effect on paroxysmal nocturnal hemoglobinuria erythrocytes of a novel therapeutic strategy for membrane-targeted delivery of a complement alternative pathway inhibitor. [Blood] Abstract

Late Stage Erythroid Precursor Production Is Impaired in Mice with Chronic Inflammation
Investigators tested the hypothesis that chronic inflammation may contribute additional features to anemia of inflammation that continue to impair erythropoiesis following the acute phase of inflammation in which hepcidin is active. [Haematologica] Full Article

Mild Hyperthermia Promotes and Accelerates the Development and Maturation of Erythroid Cells
Researchers suggest that fever-like temperatures can promote the differentiation of progenitors along the erythroid lineage and accelerate their maturation through normal regulatory circuitry. [Stem Cells Dev] Abstract

ZIP8 Zinc Transporter: Indispensable Role for Both Multiple-Organ Organogenesis and Hematopoiesis In Utero
Investigators demonstrated that ZIP8-mediated zinc transport plays an unappreciated critical role during in utero and neonatal growth, organ morphogenesis, and hematopoiesis. [PLoS One] Full Article

Hydroxyl Radical Scavenging Mechanism of Human Erythrocytes by Quercetin-Germanium (IV) Complex
This study investigated the hydroxyl-radical-scavenging mechanism of the quercertin-germanium (IV) complex to human erythrocytes, especially the effects on ultrastructure and mechanical properties of cell membrane, plasma membrane potential and intracellular free Ca²⁺ concentration. [Eur J Pharm Sci] Abstract

The HDAC Inhibitor Givinostat Modulates the Hematopoietic Transcription Factors NFE2 and C-MYB in JAK2^V617F Myeloproliferative Neoplasm Cells
Scientists investigated the mechanism of action of the HDAC inhibitor Givinostat in JAK2^V617F myeloproliferative neoplasm cells. [Exp Hematol] Abstract

CLINICAL RESEARCH

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. [N Engl J Med]
Abstract | Press Release

Extended Survival of Glioblastoma Patients after Chemoprotective HSC Gene Therapy
Investigators showed efficient polyclonal engraftment of autologous mutant methylguanine methyltransferase-modified hematopoietic stem and progenitor cells (HSC) in three patients with glioblastoma. [Sci Transl Med] Abstract | Press Release

Cotransplantation of Allogeneic Mesenchymal and Hematopoietic Stem Cells in Children with Aplastic Anemia
The authors report the preliminary results of allogeneic hematopoietic stem cell transplantation with mesenchymal stem cells for six cases of severe aplastic anemia. [Pediatrics] Abstract

AesRx Anti-Sickling Drug Aes-103 Enters Phase I/IIa Clinical Trial at NIH
AesRx, LLC, announced it has begun a Phase I/IIa clinical trial of its novel Aes-103 anti-sickling agent in patients with sickle cell disease. This trial is part of an ongoing collaboration between AesRx and the National Institutes of Health (NIH). [AesRx, LLC] Press Release

Cyclacel Announces Completion of Enrollment in Investigator-Initiated, Phase II/III Randomized Trial Comparing Sapacitabine to Low Dose Cytarabine
Cyclacel Pharmaceuticals, Inc. announced completion of enrollment of the Phase II portion of the investigator-initiated, Phase II/III multicenter, randomized trial comparing sapacitabine to low dose cytarabine in patients aged 60 years or older with previously untreated acute myeloid leukemia or high risk myelodysplastic syndromes who are unfit for intensive chemotherapy. [Cyclacel Pharmaceuticals, Inc.]
Press Release

Compassionate Use of Pluristem’s PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure
Pluristem Therapeutics, Inc. announced that a seven year-old girl suffering from an aplastic bone marrow whose condition was rapidly deteriorating is now experiencing a reversal of her condition with a significant increase in her red cells, white cells and platelets following the intramuscular injection of the company’s PLacental eXpanded (PLX) cells. [Pluristem Therapeutics, Inc.] Press Release

A Global Standard for Peer Review
After winning the strong backing of the White House, Subra Suresh convened a meeting of 47 leaders of research funding agencies from 44 countries. At the conclusion of closed-door sessions, the group will issue the first-ever global statement on the principles of merit review. [National Science Foundation, United States] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW HAA (HSANZ-ANZSBT-ASTH)-Asian-Pacific Society on Thrombosis and Haemostasis (APSTH) 2012
October 28-31, 2012
Melbourne, Australia

Visit our events page to see a complete list of events in the hematopoietic community.

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Postdoctoral Fellow in Stem Cells and Cancer (Tsinghua University)

Postdoctoral Fellow – Hematopoietic Stem Cells and Leukemia (City of Hope Beckman Research Institute)

Postdoctoral Position – Hematopoietic Stem Cell Research (University of Texas Southwestern)

Postdoctoral Fellow – Stem Cell Research (University of Texas Health Science Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.